Patent · US Active

Inhibitors of type 2 vascular endothelial growth factor receptors

US9328157B2 · kind B2 · utility

26Cited by

48References

7Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Yan Chen · Foster City, US
Elena Getmanova · Lexington, US
Martin C. Wright · Belmont, US
Alan S. Harris · Andover, US
Ai Ching Lim · Redwood City, US
Jochem Gokemeijer · Wayland, US
Lin Sun · Dedham, US
Michael Wittekind · Bainbridge Island, US

Key dates

Filing date	Nov 4, 2013
Grant date	May 3, 2016
Priority date	—
Expiry date	Nov 4, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/43
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.